Moreover, retinal protection was achieved without affecting systemic blood glucose levels in this study, suggesting the protective effects of GLP-1 are independent of blood glucose or insulin [80]
47 Visceral fat accumulation in patients with obesity causes a number of changes (oxidative stress, activation of the RAAS and gut dysbiosis), resulting in insulin resistance, increased vascular stiffness, T2D, dyslipidaemia, hypertension, coronary atherosclerosis and, ultimately, HFpEF
Nausea, vomiting and diarrhoea are some of the most common side effects
Starting a new exercise program simultaneously with a new medication is challenging
Lastly, semaglutide GLP-1 has been shown to help to reduce body weight and blood pressure, which is important for those with type 2 diabetes are may be overweight or obese